| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10918287 | Radiotherapy and Oncology | 2015 | 4 Pages | 
Abstract
												This study assessed the prophylactic bethanechol use to prevent salivary gland dysfunction during radiotherapy. A total of 97 head and neck cancer patients were allocated into two groups: Bethanechol or Placebo. Bethanechol group presented significantly improve of salivary parameters. Bethanechol was effective in decreasing the salivary gland damage.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Cancer Research
												
											Authors
												Graziella Chagas Jaguar, Eduardo Nóbrega Pereira Lima, Luiz Paulo Kowalski, Antônio Cássio Pellizzon, André Lopes Carvalho, Karina Waiswol Boccaletti, Fabio Abreu Alves, 
											